Clinical Trial Update: Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating trastuzumab deruxtecan versus endocrine therapy in HR-positive, HER2-low advanced breast cancer. The trial is currently recruiting at Y…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Trastuzumab deruxtecan (trastuzumab deruxtecan)

Snippet

Sponsor: Yonsei University | Conditions: Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative) | Phase 2 | Status: RECRUITING